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Abstract
Background: Persistent pain after inguinal herniorrhaphy is a disabling condition with a lack of evidence-based
pharmacological treatment options. This randomized placebo-controlled trial investigated the efficacy of a capsaicin 8%
cutaneous patch in the treatment of severe persistent inguinal postherniorrhaphy pain.
Methods: Forty-six patients with persistent inguinal postherniorrhaphy pain were randomized to receive either a capsaicin
8% patch or a placebo patch. Pain intensity (Numerical Rating Scale [NRS 0–10]) was evaluated under standardized
conditions (at rest, during movement, and during pressure) at baseline and at 1, 2 and 3 months after patch application.
Skin punch biopsies for intraepidermal nerve fiber density (IENFD) measurements were taken at baseline and 1 month after
patch application. Quantitative sensory testing was performed at baseline and at 1, 2, and 3 months after patch application.
The primary outcome was comparisons of summed pain intensity differences (SPIDs) between capsaicin and placebo
treatments at 1, 2 and 3 months after patch application (significance level P,0.01).
Results: The maximum difference in SPID, between capsaicin and placebo treatments, was observed at 1 month after patch
application, but the pain reduction was not significant (NRS, mean difference [95% CI]: 5.0 [0.09 to 9.9]; P= 0.046). No
differences in SPID between treatments were observed at 2 and 3 months after patch application. Changes in IENFD on the
pain side, from baseline to 1 month after patch application, did not differ between capsaicin and placebo treatment: 1.9
[20.1 to 3.9] and 0.6 [21.2 to 2.5] fibers/mm, respectively (P= 0.32). No significant changes in sensory function, sleep quality
or psychological factors were associated with capsaicin patch treatment.
Conclusions: The study did not demonstrate significant differences in pain relief between capsaicin and placebo treatment,
although a trend toward pain improvement in capsaicin treated patients was observed 1 month after patch application.
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Introduction
Inguinal herniorrhaphy is a common surgical procedure with
more than 800.000 repairs annually in the United States [1].
Persistent severe pain affecting daily activities is present in 5% of
patients [2,3] and in spite of exploratory surgery including
selective neurectomy [4,5], that has been associated with a
satisfactory outcome, the invasive nature of the procedure requires
availability of medical treatment options for patients reluctant to
undergo repeat surgery or not fit for a surgical procedure. The
evidence-base for pharmacological treatment of persistent pain
following inguinal hernia repair is nearly non-existent and
therefore it is of considerable clinical relevance to identify the
efficaciousness of drug therapy.
The capsaicin 8% cutaneous patch is used in the treatment of
peripheral neuropathic pain and significant pain-relief for up to 12
weeks has been observed in randomized, controlled trials in post-
herpetic neuralgia and HIV-related distal neuropathy [6–10].
Capsaicin is a selective agonist for the transient receptor potential
vanilloid (TRPV1) receptor residing on nociceptive peripheral
nerve fibers and keratinocytes [11]. The effect of capsaicin is
assumed to be mediated by a reversible defunctionalization of
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cutaneous nociceptors thereby inhibiting transmission of nocicep-
tive signals [12,13]. The long lasting pain relieving effect, up to
three months after a single capsaicin 8% patch application, is of
particular clinical interest. From a pharmacodynamic view, the
localized action of the capsaicin patch confers a reduced risk of
systemic side effects and a lessened potential for drug interactions.
In an un-controlled prospective study (n= 1,044) the capsaicin 8%
patch relieved pain and improved sleep quality in patients with
various peripheral neuropathic pain states [14]. Interestingly, in
this cohort 23% of the patients experienced persistent postsurgical
pain of differing etiologies. However, the efficacy of capsaicin 8%
patch treatment has never been evaluated in a randomized
controlled trial in persistent postsurgical pain. Purified capsaicin
has been shown to reduce acute postoperative pain following
inguinal hernia repair. In a randomized placebo-controlled trial
intraoperative wound instillation of purified capsaicin significantly
reduced pain scores in the capsaicin group during the first 4 days
after inguinal hernia repair [15].
In the present study we tested the hypothesis that capsaicin 8%
patch treatment would be associated with a higher analgesic
efficacy compared to placebo in patients suffering from severe
persistent inguinal postherniorrhaphy pain.
Since changes in intraepidermal nerve fiber density (IENFD)
have been observed following capsaicin 8% patch application in
healthy volunteers [16,17], we investigated the effect of capsaicin
on IENFD and sensory function, assessed by thermal and
mechanical thresholds, as secondary outcomes. Additional sec-
ondary outcomes were changes in ratings of sleep quality,
catastrophizing behaviour, anxiety and depression, associated
with capsaicin 8% patch treatment.
Materials and Methods
A randomized, double-blind, placebo-controlled, parallel-group
study was conducted at the Multidisciplinary Pain Center,
Rigshospitalet, Copenhagen with patients recruitment from
August 2012 to May 2013 and follow-up from September 2012
to September 2013. Study approval was obtained from the
Committee on Health Research Ethics of the Capital Region of
Denmark (H-4-2012-055), the Danish Data Protection Agency,
the Danish Medicines Agency (EudraCT-Nr. 2012-001540-22)
and the study was registered at ClinicalTrials.gov
(NCT01699854). The study was conducted in accordance with
Good Clinical Practice (GCP) Guidelines and was monitored by
the Copenhagen University Hospital GCP Unit. The protocol for
this trial and supporting CONSORT checklist are available as
supporting information; see Checklist S1 and Protocol S1.
Patients eligible in the study were referred to the Multidisci-
plinary Pain Center by a surgeon or a general practitioner and
written informed consent was obtained from all patients. Patients
were $18 years with severe unilateral persistent inguinal
postherniorrhaphy pain (numerical rating scale [NRS, 0–10] $
5) for more than 6 months. Concomitant analgesic medication was
allowed if patients had maintained a stable regimen for at least 4
weeks prior to study entry and stayed on stable doses throughout
the study period. Exclusion criteria were allergy to capsaicin or
vehicle-ingredients in the patch, skin lesions or inflamed skin at the
application site, bilateral groin pain, severe cardiac impairment,
known diseases impairing nervous system function, alcohol or drug
abuse, inability to understand Danish, and in female patients
lactation or pregnancy (negative pregnancy test required for
females of fertile age).
Randomization
Randomization was done by Herning Hospital Pharmacy
according to a computer-generated randomization list (http://
randomization.com/) and a block-size of four was used.
Pain assessment
Patients evaluated pain intensities (NRS) every morning and
evening, at rest in the supine position, during transition from
supine to standing position, and during the patient’s palpation of
the point of maximum pain in the groin. Assessments were made
in the 3 days preceding the patch treatment (baseline) and in the
3 days preceding the clinical visits at 1, 2 and 3 months after patch
application.
Questionnaires
Questionnaires were completed at baseline and at 1, 2 and 3
months after patch application. Anxiety and depression were
evaluated with the Hospital Anxiety and Depression Scale (HADS)
[18] and the level of catastrophizing behaviour with the Pain
Figure 1. Study algorithm, CV=Clinical visit, Q’s =Questionnaires.
doi:10.1371/journal.pone.0109144.g001
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Catastrophizing Scale (PCS) [19]. Pain-related sleep interference
was evaluated with the Daily Sleep Interference Scale (DSIS [0–
10, 0 = pain did not interfere with sleep, 10= pain completely
interfered with sleep]) [20]. The self-report version of the Leeds
Assessment of Neuropathic Symptoms and Signs pain scale (S-
LANSS) was used for assessment of neuropathic pain components
[21].
Quantitative sensory testing (QST)
Prior to the QST, hair growth in the inguinal and suprapubic
areas was carefully trimmed using a surgical clipper (3M-9671, St.
Paul, MN). The QST assessments were performed in accordance
with previous studies in persistent inguinal postherniorrhaphy pain
[22,23]. The sensory testing area on the pain side included the
point of maximum pain and in addition the contralateral inguinal
region was used as a control area. The warmth and cool detection
thresholds (WDT, CDT) and the heat pain threshold (HPT) were
determined using a computer controlled thermode (Somedic AB,
Ho¨rby, Sweden; contact area 2.565.0 cm2). The baseline
temperature was 32uC and thermal stimuli were delivered with a
ramp rate of61uC/s with cut-off values of 50uC for heat, and 5uC
for cold stimuli. The pressure pain threshold (PPT) was assessed at
the point of maximum pain using a handheld pressure algometer
(Somedic AB, Ho¨rby, Sweden; 1 cm2 felt-tipped probe) applied
perpendicularly to the skin, until the pressure was perceived as
painful or exceeded the cut-off value of 350 kPa. A heat stimulus
(5 s at 47uC, ramp rate 1uC/s) was delivered at the point of
maximum pain to evaluate the suprathreshold heat pain percep-
tion (STH) rated by the patient (NRS). All QST parameters were
assessed three times and the median values were used. The QST
was performed at baseline and at the clinical visits: at 1 month (day
30–36), 2 months (day 60–66), and 3 months (day 90–96) after
patch application (fig. 1).
Figure 2. Flow diagram of patients in the study. ` Data from these two patients were included in the analyses up to the time of the medication
violation. NRS=Numerical Rating Scale.
doi:10.1371/journal.pone.0109144.g002
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Skin biopsies
At baseline and at the clinical visit at 1 month after patch
application two 3-mm skin punch biopsies (disposable biopsy
punch, Miltex, York, PA) were performed, using a sterile
technique, at the point of maximum pain in the groin and on
the contralateral control side. Prior to biopsies, the skin areas were
anesthetized with 1–2 ml of mepivacaine (10 mg/ml, AstraZeneca
AB, So¨derta¨lje, Sweden). The IENFD was estimated in agreement
with previously described methods [23,24]. After fixation with 4%
paraformaldehyde, the biopsies were washed in phosphate buffer
and then stored in 10% sucrose with 0.1 M phosphate buffer at
4uC, until analysis. Sections of 50-mm thickness were immuno-
stained with the pan-neuronal marker PGP-9.5 (1:800, Ultraclone,
Wellow, UK) and visualized with Cy3-coupled anti-rabbit
antibodies (1:100, Amersham Biosciences, Piscataway, NJ). Intra-
epidermal nerve fiber counting was performed with a light-
microscope (Zeiss Axiophot 2, Wetzlar, Germany) and Spot
advanced software (Windows Version 4.5, Sterling Heights, MI).
The skin biopsies were analyzed blinded in regard to side.
Treatment procedure and blinding method
The research nurse and the physician responsible for the
intervention did only meet the patient on the day of treatment and
were not further involved in the study. The research nurse
delineated the patch area corresponding to the inguinal pain
distribution including the point of maximum pain. Patients were
pre-treated with a topical local anesthetic cream (EMLA,
lidocaine/prilocaine 25 mg/25 g, AstraZeneca AB, So¨derta¨lje,
Sweden) 60 min before patch application. The patch application,
patch removal, and skin cleansing were done by a physician.
During this procedure the research nurse was not allowed
presence in the treatment room since minute quantities of
aerosolized capsaicin-particles during patch handling could have
led to accidental un-blinding of the research nurse.
The capsaicin patches (capsaicin 640 mg/cm2, 8% w/w; Astellas
Pharma Europe B.V., Leiderdorp, The Netherlands) and the
inactive placebo patches were identical in appearance and
composition (in regard to vehicle substances). An inactive placebo
patch was used since an active placebo patch was not obtainable
from the manufacturer of the capsaicin patch. The patients were
informed that they might experience pain during and after the
patch application. The patches were applied in the groin area for
60 min. After patch removal a cleansing gel (Astellas Pharma
Europe B.V., Leiderdorp, The Netherlands) was applied in order
to remove capsaicin residues. In order to decrease local irritation
of the skin cool packs (assistCo AS, Rjukan, Norway) were
administered for 45–60 minutes after patch removal. Patients were
told to use oral acetaminophen 1 g every 6 h and ibuprofen
400 mg every 6 h for up to 3 days as needed after patch
application. The patients and investigators were blinded to the
treatment allocation throughout the study. At the clinical visit 1
month after patch application patients were asked to report if they
had experienced application site skin reactions (erythema, pain,
burning sensation) or any other adverse events. To evaluate
patient blinding we asked patients at the clinical visit 1 month after
patch application to verbally report which treatment they had
received.
Table 1. Baseline patient characteristics.
Capsaicin (n =24) Placebo (n =22)
Age (yrs){ 52 (17) 55 (14)
Sex (male/female) 20/4 22/0
BMI (kg/m2) ` 25 (23–30) 26 (23–28)
Duration of pain (mo)` 37 (22–58) 39 (18–63)
Primary/recurrent operation1, n 20/4 20/2
Open mesh/laparoscopic1, n 21/3 17/5
Unilaterally/bilaterally operated, n 23/1 17/5
Exploratory surgery for pain, yes/no, n 10/14 7/15
Concomitant pain medication, yes/no, n 11/13 13/9
- Acetaminophen, n 7 7
- NSAIDs, n 3 7
- Gabapentin, n 2 4
- Tricyclic antidepressants, n 1 2
- Opioids, n 2 2
Baseline pain ratings"
- Pain at rest (NRS) 4 (3–7) 4 (3–6)
- Pain during movement (NRS) 5 (4–7) 6 (3–7)
- Pain during palpation (NRS) 7 (5–9) 7 (5–8)
{Mean (standard deviation).
`Median (25–75% interquartile range).
1Pain-generating inguinal hernia operation.
"Pain ratings at baseline assessed at rest in the supine position, during transition from supine to standing position, and during the patient’s palpation of the point of
maximum pain in the groin. Values are medians (25–75% interquartile range). Two patients who withdrew early from the study and one patient who was lost to follow-
up did not report baseline pain ratings and were not included in the analyses of pain ratings.
BMI = Body Mass Index, NRS =Numerical Rating Scale (0–10), NSAIDs =Non-steroidal Anti-inflammatory Drugs.
doi:10.1371/journal.pone.0109144.t001
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Statistical analyses
The pain intensities during the 3 standardized conditions (at
rest, during movement and pressure evoked), were evaluated twice
daily in the 3 days preceding patch treatment (baseline) and in the
3 days preceding the clinical visit at 1, 2 and 3 months after patch
application. The median value of the 3 standardized pain
assessments was used to calculate the summed pain intensity
(SPI) values (containing 6 median values [pain assessments twice
daily for 3 days]) in accordance with a previously described
method [23]. The summed pain intensity differences (SPID) were
Figure 3. Panel A. Summed pain intensity (SPI) values assessed on a Numerical Rating Scale (NRS) at baseline and at 1, 2 and 3
patch application. Each SPI-value contains six median values (pain assessments twice daily for three days) and the maximum SPI-value is 60 NRS
units. Values are mean (95% confidence interval). Black line (#) placebo treated patients. Red line ( ) capsaicinN treated patients. Individual time
profiles are displayed for placebo treated patients (panel B, black lines) and capsaicin treated patients (panel C, red lines). The arrow (panel C)
indicates patient #10 with baseline median NRS-value of 0 (see text for explanation). doi:10.1371/journal.pone.0109144.g003
Table 2. Changes in pain intensity between baseline and 1 month after patch application presented as SPID for capsaicin and
placebo patch treatments, and the mean difference.
Capsaicin (n=22) Placebo (n =20) Difference P-value
SPID (NRS) 4.8 (1.4 to 8.2) 20.2 (23.8 to 3.4) 5.0 (0.09 to 9.9) 0.046
SPID % 19.8 (7.5 to 32.1) 21.0 (214.1 to 12.1) 20.9 (2.9 to 38.9) 0.024
The SPID was calculated as the difference between the baseline SPI-value and the SPI-value at 1 month after patch application. Each SPI- value contains six median
values (pain assessments twice daily for three days). Values are mean (95% CI). Positive values of SPID indicate pain reduction after treatment. P-values indicate
comparisons of SPID (capsaicin vs. placebo).
NRS =Numerical Rating Scale (0–10), SPID = Summed pain intensity difference, SPI = summed pain intensity.
doi:10.1371/journal.pone.0109144.t002
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 months after
calculated for 1, 2 and 3 months after patch application, as the
difference between the baseline SPI-value and the post-treatment
SPI-value. The primary outcome was comparisons of SPIDs
between capsaicin and placebo treatments at 1, 2 and 3 months
after patch application. No data from previous studies were
available and the a priori sample size calculation was therefore
based on the best estimates for the study cohort. Based on a
significance level of 0.01 (a), a power of 0.9 (b=0.1), an estimated
standard deviation for the SPI assessments of 3.1 (NRS), and a
minimal relevant difference for the six SPI assessments of 4.5
(NRS), the estimated number of patients needed in each group
were 24 (48 in total). In order to compensate for dropouts the
number of patients was set to 50. Due to uncertainties in the power
calculation an interim analysis by an independent statistician was
planned a priori following completion of the first 32 patients.
Linear regression analyses for repeated measures (a mixed
model method) were used to evaluate the treatment effects over
time. The summed pain intensity difference (SPID) was the
outcome variable and treatment group (capsaicin or placebo) and
time (1, 2 and 3 months after patch application) were explanatory
variables. While measurements taken at different time points were
expected to correlate, we also assumed that measurements taken at
adjacent time points were more correlated than measurements
further apart, and therefore we used an unstructured covariance
structure (all covariance parameters are freely estimated). We used
the PROC MIXED procedure and the repeated statement in SAS
software (9.3, SAS Institute Inc., Cary, NC) to estimate the model.
We included the interaction because we were interested in testing
whether potential group differences changed over time. The mixed
model is dealing with missing longitudinal measures and the
analysis included all patients with at least one SPID-value. For
secondary outcomes, including QST variables and questionnaire
scores (DSIS, HADS, PCS, S-LANNS), differences (D) between
post-treatment follow-up and baseline values were used to
compare capsaicin and placebo patch treatments. The numbers
of patients included in the data analyses vary for different outcome
measures and are indicated in the tables for each analysis.
The normality of data was assessed with the Kolmogorov-
Smirnov test and visual estimation of relevant residual distribution
plots. Comparisons between treatment groups were performed
with unpaired t-tests (normally distributed data) and the Mann-
Whitney tests (non-normally distributed data). Fischer’s exact test
was used to compare proportions. Statistical analyses were
conducted using SPSS software (SPSS 20.0, Chicago, IL) and
MedCalc Software (12.3.0.0, Mariakerke, Belgium). The linear
regression analyses for repeated measures were performed with
SAS software. Due to the three statistical tests performed
(comparisons 1, 2 and 3 months after patch application) and the
planned interim analysis, thus increasing the probability of a type I
error, all results were considered significant at P,0.01 (two-tailed).
Results
A total of 46 patients were randomized (fig. 2). Baseline patient
characteristics and pain ratings are shown in table 1. In one
patient (#46) severe pain at the application site necessitated
premature patch removal leading to study withdrawal. In two
patients (#16, #34) add-on treatment with other analgesics was
initiated during the study. Data from these two patients were
included in the analyses only up to the time of the violation of the
medication criterion. One patient (#10) reported severe pain
(NRS $5) at the first clinical visit and was thus included in the
study in accordance with the protocol. However, in the pain diary
evaluations preceding the patch application the patient only
reported pain during palpation (NRS=5), and, no pain (NRS=0)
at rest and during movement Therefore, the median NRS-value of
the three standardized pain assessments at baseline was 0 for this
patient (indicated in Fig. 3C). Five patients had one or more
missing SPID values. Three patients (#4, #15, #49) had one
Table 4. Assessments of intraepidermal nerve fiber density (IENFD) on the pain side at baseline and at 1 month after patch
application.
Baseline
(IENFD/mm)
1 month
(IENFD/mm) D value P-value
Capsaicin (n = 18) 4.8 (2.5 to 7.2) 2.9 (1.2 to 4.7) 1.9 (20.1 to 3.9) 0.32
Placebo (n = 20) 5.8 (3.2 to 8.3) 5.2 (2.2 to 8.1) 0.6 (21.2 to 2.5)
Values are mean (95% CI). The P-value indicates comparison of D values (capsaicin vs. placebo unpaired t-test). D value =baseline –1 month value. D values are normally
distributed while baseline and 1 month IENFD values are non-normally distributed.
doi:10.1371/journal.pone.0109144.t004
Table 3. Differences in quantitative sensory assessments on the pain side from baseline to 1 month after patch application.
D-value Capsaicin (n=21) Placebo (n =19) P-value
DWDT1 (uC) 0.2 (20.9 to 1.2) 0.6 (20.1 to 1.3) 0.52`
DCDT (uC) 0.0 (20.8 to 0.7) 20.1 (20.7 to 0.8) 0.96
DHPT (uC) 0.3 (20.4 to 1.5) 0.3 (20.2 to 1.2) 0.91
DPPT1 (kPa) 1.5 (224.8 to 27.8) 20.4 (223.2 to 22.4) 0.91`
DSTH (NRS) 0.0 (21.0 to 0.0) 0.0 (21.0 to 1.0) 0.56
Values are mean (95% CI)1 or median (95% CI). D value = post-treatment minus baseline value. P-values indicate comparisons of D-values (capsaicin vs. placebo
[unpaired t-test` or the Mann-Whitney test). Positive D-values for WDT, HPT, PPT and CDT indicate increased thresholds after treatment.
WDT=warmth detection threshold, CDT = cool detection threshold, HPT = heat pain threshold, PPT = pressure pain threshold, STH= suprathreshold heat pain
perception, NRS =Numerical Rating Scale (0–10).
doi:10.1371/journal.pone.0109144.t003
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missing SPID value and two patients (#2, #34) had two missing
SPID values.
As previously mentioned, an interim analysis was planned for
the first 32 patients, but due to a lower patient-recruitment rate
than anticipated and a premature expiry date of the placebo
patches (May 2013) an interim analysis could not be performed.
The interim analysis would have impeded study progression and
prolonged the study for an estimated period of at least three
months (time from patch application to study completion; fig. 1).
Therefore, it was decided to continue the study without an interim
analysis and to recruit patients until the expiration date of the
placebo patch: the actual number of randomized patients (n = 46)
in the study were thus lower than the originally estimated sample
size of 50 patients.
Pain
The summed pain intensity (SPI) values (NRS) at baseline and
at 1, 2 and 3 months after patch application are presented in
(fig. 3). A linear regression analysis for repeated measures with
SPID as outcome variable and treatment group (capsaicin [n = 22]
or placebo [n= 20]) and time (1, 2 and 3 months after patch
application) as explanatory variables revealed a significant
interaction for group * time (F2,37.4 = 5.53, P=0.008). The
analysis showed that the maximum difference in SPID between
capsaicin and placebo treated patients was observed at 1 month
after patch application, although statistical significance at the 0.01
level was not achieved. The mean difference [95% CI] in SPID at
1 month after patch application was (5.0 [0.09 to 9.9] NRS-units;
P=0.046, table 2), corresponding to a mean difference [95% CI]
in SPID percentage of (20.9% [2.9 to 38.9%]; P=0.024).
Similarly, there were no significant differences in SPID between
capsaicin and placebo patch treatments at 2 months after patch
application (mean difference [95% CI]: 21.7 [26.4 to 3.1] NRS-
units; P=0.48) or at 3 months after patch application (mean
difference [95% CI]: 3.6 [23.1 to 10.2] NRS-units; P=0.29).
Sensory Function
Analyses of changes in QST assessments from baseline to 1
month after treatment are presented in table 3. No significant
differences between capsaicin and placebo patch treated patients
for thermal thresholds, suprathreshold heat pain perception, and
pressure pain thresholds were observed.
Skin innervation
The median (95% CI) IENFD at baseline was significantly
lower on the pain side, i.e. 4.3 (1.5 to 6.8) fibers/mm compared
with the non-pain side 8.6 (7.4 to 11.0) fibers/mm, (P,0.0001,
Wilcoxon signed rank test). Changes in IENFD, from baseline to 1
month after patch application on the pain side, did not differ
between capsaicin and placebo treated patients (P=0.32, table 4).
S-LANSS, Sleep Quality and Psychological Factors
At baseline the median (95% CI) S-LANSS score was 15 (10 to
17) and 26 of 42 patients (62%) reported a S-LANSS score of $12
indicating pain components of predominantly neuropathic origin
[21]. Changes from baseline to 1 month after patch application
with regard to sleep quality, PCS, S-LANSS, and HADS scores
did not differ between capsaicin and placebo treated patients.
Adverse Events
Seventeen of 23 (74%) capsaicin treated patients and 6 of 20
(30%) placebo treated patients reported one or more skin reactions
on the application site (P=0.006, Fischer’s exact test, table 5). No
other adverse events or complications were observed in the study.
Patient Blinding
Sixteen of 23 patients (70%) treated with the capsaicin patch
and 17 of 21 patients (81%) treated with the placebo patch
correctly identified their treatment allocation (P=0.49, Fischer’s
exact test).
Discussion
The present study in patients with severe persistent inguinal
postherniorrhaphy pain, comparing the pain relief of a capsaicin
8% patch with an inactive placebo patch, was not able to
demonstrate significant differences in pain reduction during
standardized testing conditions. In addition, we did not observe
any changes in secondary outcome variables including sensory
function, IENFD, sleep quality, catastrophizing behaviour (PCS),
or anxiety and depression (HADS) scores associated with capsaicin
patch treatment.
Statistical Issues
Interpretation of the study’s main finding should consider the a
priori assigned significance level of 0.01. The authors regarded this
conservative statistical measure a precaution against the introduc-
tion of type I errors due to the use of multiple comparisons and
interim analysis. However, the statistical comparisons of SPID-
scores, one month after patch application, yielding P-values of
0.024 and 0.046, indicated a trend of an improved pain relief in
capsaicin treated patients. A potential contributing factor to the
non-significant findings is obviously the premature discontinuation
of the study after 46 randomized patients compared to the a priori
estimated sample size of 50 patients. This circumstance may have
introduced a type II error. A post hoc power calculation could be
considered but is generally not recommended [25].
Skin innervation
The study corroborates our previous findings of a reduced
IENFD on the pain side compared to the contralateral side in
persistent inguinal postherniorrhaphy pain patients, most likely
Table 5. Skin reactions at application site.
Capsaicin (n =23) Placebo (n=20)
Any application site reaction, n (%) 17 (74) 6 (30)
- Erythema, n 9 3
- Pain, n 12 6
- Burning sensation, n 12 1
doi:10.1371/journal.pone.0109144.t005
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caused by surgical nerve injury [23,26]. Several studies in healthy
volunteers have demonstrated a 60–80% reduction in IENFD one
week after capsaicin 8% patch treatment [16,17,27]. The current
study, the first to evaluate changes in IENFD following capsaicin
patch treatment in patients, failed to show a significant difference
in IENFD between treatment groups. A plausible explanation is
the low baseline IENFD on the pain side in postherniorrhaphy
pain patients compared to healthy volunteers, making it difficult to
demonstrate a further reduction in IENFD following capsaicin
treatment. The small group size may be another reason why the
observed reduction of IENFD in the capsaicin group did not reach
significance. However, it should be emphasized that none of the
studies investigating IENFD after application of an 8% capsaicin
patch in healthy volunteers provide data at 4 weeks after
application [16,17,27], and it cannot be excluded that partial
regeneration of nerve fibers already may have taken place [28].
Sensory Assessments
The QST assessment did not demonstrate any differences in
cutaneous (thermal) or deep tissue (mechanical) sensory function
between capsaicin and placebo treatment. A possible explanation
is the previously mentioned lack of a significant reduction in
IENFD after capsaicin treatment. In addition, sensory nerve
endings not expressing TRPV1 receptors, i.e. Ab-fibers, the
majority of Ad-fibers, and a subgroup of C-fibers, remain intact
after capsaicin treatment and are thus still capable of transmitting
sensory stimuli [12]. Accordingly, previous studies in neuropathic
pain patients have failed to demonstrate sensory impairment after
capsaicin patch treatment. In painful HIV-related neuropathy no
differences in thermal and vibration detection thresholds were
observed between capsaicin treated patients and controls at 4 and
12 weeks after patch application [9]. Furthermore, no differences
between treatment groups were found in two studies investigating
detection thresholds for brush, punctate stimulation, vibration and
warmth in patients with post-herpetic neuralgia at 4 and 12 weeks
after patch application [8,29].
Limitations
A confounding factor for the study is the patient-blinding. The
higher incidence of local side effects experienced by patients in the
capsaicin group (74%) compared to the placebo group (30%), and
the correspondingly high proportion of patients who correctly
identified their treatment allocation, indicate an insufficient
blinding-technique. Therefore, it cannot be excluded that the
potential analgesic effect experienced by the capsaicin treatment
may in fact represent a placebo effect. The short duration of the
potential analgesic effect (i.e. one month) also may connote to a
placebo effect. The study thus supports the use of an active
placebo (e.g. low-dose of capsaicin) in order to ensure adequate
blinding in future studies assessing the effects of topical capsaicin.
Pathophysiological Mechanism
Pain relief up to 12 weeks after capsaicin patch application has
been observed in previous randomized, controlled trials in post-
herpetic neuralgia and HIV-related distal neuropathy [6–10]. The
lack of a significant analgesic effect in the present study may be
explained by a different pain mechanism in persistent inguinal
postherniorrhaphy pain. The S-LANNS findings in the present
study and the QST results in previous studies [30,31] point
towards neuropathic pain components in this patient cohort,
which is also underscored by the reduced IENFD on the painful
side, specifying a small-fiber neuropathy. However, a number of
postherniorrhaphy pain patients demonstrate decreased pain
thresholds to pressure algometry indicating increased deep tissue
sensitivity and suggesting deep pain components that may be
caused by an untoward inflammatory reaction to the implanted
mesh [31]. The negative findings in our study suggest that
interruption of cutaneous nerve transmission alone may be
insufficient to relieve pain substantially in these patients and seem
to indicate that nerve injury, as well as deep tissue inflammation,
may contribute to the development and maintenance of persistent
postherniorrhaphy pain. Further studies are needed to elucidate
the pathophysiological contributors in persistent postherniorrha-
phy pain in order to guide future treatment strategies.
In conclusion capsaicin patch 8% did not significantly reduce
combined static and dynamic pain components compared to
placebo in persistent inguinal postherniorrhaphy pain, albeit a
trend towards pain relief was observed 1 month after capsaicin
patch application.
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